Has Announced the Appointment of Christian Burks As Chief Scientific

PEOPLE

Affinium Pharmaceuticals (Toronto, Ontario, joined the company as senior vice president, Canada) has announced the appointment of research and preclinical development. Dr. Christian Burks as chief scientific officer. Dr. Miletich was most recently senior vice presi- Burks was most recently vice president and dent for worldwide preclinical development chief informatics officer at Exelixis. at Merck Research Laboratories.

OXiGENE (Watertown, MA) has appointed Gilead Sciences (Foster City, CA) has named Frederick Driscoll as CEO, replacing Bjorn John F. Milligan senior vice president and Nordenvall. Dr. Nordenvall will remain on CFO. Dr. Milligan joined Gilead in 1990 and the board of directors as vice chairman and served most recently as vice president, cor- serve as a strategic consultant to the compa- porate development. Sharon Surrey- ny. Prior to joining OXiGENE as president Barbari, who joined Gilead in 1998 and has and CFO in October 2000, Mr. Driscoll served as vice president and CFO since served as senior vice president of finance and February 2000, has announced her resigna- operations at Collagenesis. tion from the company.

CuraGen (New Haven, CT) has announced Orchid BioSciences (Princeton, NJ) has the elections of David R. Ebsworth and John appointed Kenneth D. Noonan to its board H. Forsgren to its board of directors. Dr. of directors to replace Anne VanLent, who Ebsworth was formerly president and gener- resigned in 2001. Dr. Noonan is a partner at al manager of the pharmaceutical business LEK Consulting and leads the firm’s life sci- group for Bayer AG, and Mr. Forsgren is vice ences practice in the UK and Europe. Prior chairman of the board and CFO of to joining LEK, Dr. Noonan was senior vice Northeast Utilities. In addition, Richard H. president of corporate development for Booth, CEO of HSB Group, has stepped Applera Corp. down from CuraGen’s board, but will remain an advisor to the company. Jean O’Connor has been named to the newly created position of vice president, quality Rigel Pharmaceuticals (S. San Francisco, assurance at Genta (Berkeley Heights, NJ). CA) has announced the appointment of She comes to the company after more than 20 Elliott Grossbard as senior vice president of years at Johnson & Johnson, where she held medical development. Prior to joining Rigel, positions of increasing responsibility in regu- Dr. Grossbard was vice president, clinical latory affairs and quality assurance within © http://biotech.nature.com Group 2002 Nature Publishing affairs for Avigen. numerous divisions including the R.W. Johnson Pharmaceutical Research Institute, Wayne T. Hockmeyer has been elected to the Ortho Biotech, and Ortho Diagnostics. board of directors of Novirio Pharmaceuticals (Cambridge, MA). Dr. Hockmeyer founded Michael S. Richman has joined MacroGenics MedImmune in 1988, served as its president (Rockville, MD) as executive vice president and CEO until October 2000, and is currently and chief operating officer. He was formerly chairman of its board of directors. senior vice president of corporate development and administration at MedImmune. In Neil Kurtz has been named president, CEO, addition, MacroGenics has named Kathryn and a board member of Neurogenetics (La E. Stein as vice president for product devel- Jolla, CA). Dr. Kurtz was previously presi- opment and regulatory affairs. Dr. Stein has dent at Ingenix Pharmaceutical Services, a been a member of the Center for Biologics division of United Healthcare Group, and a Evaluation and Research (CBER) at the US cofounder, president, and CEO of FDA since 1980 and has served as director of Worldwide Clinical Trials. the division of monoclonal antibodies since its inception in 1992. Therion Biologics (Cambridge, MA) has announced the appointment of Mark Marc Vasseur has been Leuchtenberger as president and CEO. Mr. named senior vice presi- Leuchtenberger joins the company from dent of Genset (Paris), Biogen, where he served most recently as with responsibility for the vice president, international. Dennis L. development of strategic Panicali, who founded Therion and has projects in the central ner- served as president and CEO for the last 11 vous system field. Mr. years, will serve as the company’s first chief Vasseur cofounded Genset in 1989 and scientific officer and will also remain a mem- served as chief biology officer until July ber of the board of directors. 2000. In August 2000, he founded Pasteur Mediavita, a life-science multimedia pub- Amgen (Thousand Oaks, CA) has lishing company, and held the position of announced that Joseph P. Miletich has CEO until March 2002.

http://biotech.nature.com • MAY 2002 • VOLUME 20 • nature biotechnology 521